Method of reducing immunogenicity of toxicity of an antibody of IgG class
AssigneeNeoRx Corporation
InventorsScott S. Graves, John M. Reno, Robert W. Mallett, Mark D. Hylarides, Stephen M.J. Searle, Andrew H. Henry, Jan T. Pedersen, Anthony R. Rees
Life of this patent
Estimating the term…
Abstract
Humanized antibodies which bind the NR-LU-13 antigen, conjugates containing such antibodies, and their use in pretargeting methods and conventional antibody therapy and immunodiagnosis are provided.
Claims50
A humanized antibody or an antigen-binding humanized antibody fragment, wherein said antibody or said antibody fragment binds specifically to the antigen bound by antibody NR-LU-13.
A method of reducing immunogenicity or toxicity of an antibody or an antigen-binding antibody fragment of IgG class, comprising the steps of:
- (a) selecting a host system for the characteristic that said system does not N-link glycosylate an antibody or an antibody fragment;
- and
- (b) expressing in said host system a nucleotide sequence comprising nucleic acids encoding an IgG antibody or an antigen-binding antibody fragment.
A method of eliminating N-linked glycosylation in an antibody or an antigen-binding antibody fragment of IgG class to reduce immunogenicity or toxicity, comprising expressing in a host system a nucleotide sequence comprising nucleic acids encoding an IgG antibody or an antigen-binding antibody fragment, wherein said host system does not N-link glycosylate said antibody or said antibody fragment.
A method of modifying the N-linked glycosylation of an antibody or an antigen-binding antibody fragment of IgG class, comprising subjecting said antibody or antibody fragment to a post expression modification that modifies the N-linked glycosylation.
The humanized antibody NRX451 or an antigen-binding fragment thereof.
Dependencies are inferred from the claim text.